CITIGROUP INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
CITIGROUP INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$157,000
-29.9%
133,051
-16.2%
0.00%
Q2 2023$223,867
-67.8%
158,771
-65.7%
0.00%
Q1 2023$694,326
+24.4%
462,884
-3.0%
0.00%
Q4 2022$558,294
+262.5%
477,174
+250.9%
0.00%
Q3 2022$154,000
+1825.0%
135,981
+2657.7%
0.00%
Q2 2022$8,000
-42.9%
4,931
-45.4%
0.00%
Q1 2022$14,000
-83.9%
9,037
-74.6%
0.00%
Q4 2021$87,000
-74.9%
35,607
-74.2%
0.00%
Q3 2021$347,000
+951.5%
137,858
+1082.0%
0.00%
Q2 2021$33,000
+73.7%
11,663
+43.4%
0.00%
Q1 2021$19,000
+90.0%
8,136
+38.1%
0.00%
Q4 2020$10,000
+66.7%
5,8910.0%0.00%
Q3 2020$6,000
+20.0%
5,8910.0%0.00%
Q2 2020$5,000
-83.9%
5,891
-84.1%
0.00%
Q1 2020$31,000
+3.3%
37,110
+8.6%
0.00%
Q4 2019$30,000
+100.0%
34,175
+119.1%
0.00%
Q3 2019$15,00015,5980.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders